LENSAR INC
LNSRNASDAQTrading Snapshot
- Day Range
- $6.82 – $7.02
- 52-Week Range
- $4.95 – $12.94
- Volume
- $4.78B
- Avg Volume
- $6.23B
- Shares Outstanding
- 12.3M
- Next Earnings
- Nov 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $58M
- Last Q Revenue
- $16M
- P/E Ratio
- 2.4
- P/S Ratio
- 1.4x
- EPS (TTM)
- $2.08
- Dividend Yield
- —
- Dilution (1yr)
- +3.8%
Why Investors Own LNSR
- ✓High-growth profile — revenue up +52.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 77% gross margin and 16% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
LENSAR INC
LNSR
StockOtter · stockotter.spaceAbout LENSAR INC
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
LENSAR Q2 Earnings Call Highlights
LENSAR NASDAQ: LNSR reported second-quarter 2026 revenue growth of 18% as the company continued to rebuild commercial momentum following the termination of its proposed merger with Alcon near the end of the first quarter
LENSAR, Inc. (LNSR) Q2 2026 Earnings Call Transcript
LENSAR, Inc. (LNSR) Q2 2026 Earnings Call Transcript
LENSAR® Reports Second Quarter 2026 Results and Provides Business Update
10 ALLY Robotic Cataract Laser Systems® (“ALLY System”) Placements in Second Quarter 2026; Backlog of 13 ALLY Systems as of June 30, 2026 Second Quarter Recurring Revenue was $13.7 million Total Laser Installed Base Clim
LENSAR Shareholders Re-Elect Directors, Back Executive Pay at 2026 Annual Meeting
LENSAR (NASDAQ: LNSR) shareholders elected three Class III directors, ratified the appointment of PricewaterhouseCoopers LLP as the company's independent auditor and approved advisory proposals on executive compensation